#BEGIN_DRUGCARD DB00388

# AHFS_Codes:
12:12.04
52:24.00
52:32.00
84:92.00

# ATC_Codes:
C01CA06
C05AX03
R01AA04
R01AB01
R01BA03
S01FB01
S01GA05

# Absorption:
Completely absorbed after oral administration. It has a reduced bioavailability (compared to pseudoephedrine) following oral administration due to significant first-pass metabolism in the intestinal wall. Compared to IV administration, bioavailability is approximately 38%. Peak serum concentrations are achieved approximately 0.75-2 hours following oral administration. Phenylephrine should be administered parenterally to achieve cardiovascular effects. Occasionally, systemic effects are observed following oral inhalation.

# Biotransformation:
Undergoes extensive first-pass metabolism in the intestinal wall and extensive metabolism in the liver. Sulfate conjugation, primarily in the intestinal wall, and oxidative metabolism by monoamine oxidase (MAO) represent the principle routes of metabolism. Glucuronidation occurs to a lesser extent. Phenylephrine and its metabolites are mainly excreted in urine/
.

# Brand_Mixtures:
AK Vernacon Oph Soln (Pheniramine Maleate + Phenylephrine Hydrochloride)
Biohisdex DM Decongestant (Dextromethorphan Hydrobromide + Diphenylpyraline Hydrochloride + Phenylephrine Hydrochloride)
Biohisdine DM Decongestant (Dextromethorphan Hydrobromide + Diphenylpyraline Hydrochloride + Phenylephrine Hydrochloride)
Chemhisdex DM Decongestant (Dextromethorphan Hydrobromide + Diphenylpyraline Hydrochloride + Phenylephrine Hydrochloride)
Chemhisdine DM Decongestant (Dextromethorphan Hydrobromide + Diphenylpyraline Hydrochloride + Phenylephrine Hydrochloride)
Citron Chaud Cumberland Pws (Acetaminophen + Pheniramine Maleate + Phenylephrine Hydrochloride + Vitamin C)
Citron Chaud DM Cumberland Pws (Dextromethorphan Hydrobromide + Pheniramine Maleate + Phenylephrine Hydrochloride + Vitamin C)
Codalin (Codeine Phosphate + Diphenylpyraline Hydrochloride + Phenylephrine Hydrochloride)
Cold & Allergy (Brompheniramine Maleate + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Cold & Allergy Relief - Liq (Brompheniramine Maleate + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Cough, Cold & Allergy Relief (Brompheniramine Maleate + Dextromethorphan Hydrobromide + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
DayQuil (Acetaminophen + Dextromethorphan + Phenylephrine)
Decongestant Antihistaminic Syrup (Brompheniramine Maleate + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Dimetane Expectorant Liq (Brompheniramine Maleate + Guaifenesin + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Dimetane Expectorant-C Syr (Brompheniramine Maleate + Codeine Phosphate + Guaifenesin + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Dimetane Expectorant-DC Syr (Brompheniramine Maleate + Guaifenesin + Hydrocodone Bitartrate + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Dimetapp (Brompheniramine Maleate + Phenylephrine Hydrochloride)
Dimetapp Cold & Sinus (Acetaminophen + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Dimetapp DM Elixir (Brompheniramine Maleate + Dextromethorphan Hydrobromide + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Dimetapp DM Tab (Brompheniramine Maleate + Dextromethorphan Hydrobromide + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Dimetapp Elixir (Brompheniramine Maleate + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Dimetapp Extentabs (Brompheniramine Maleate + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Dimetapp Extra Strength (Brompheniramine Maleate + Phenylephrine Hydrochloride)
Dimetapp Oral Infant Cold Drops (Brompheniramine Maleate + Phenylephrine Hydrochloride)
Dimetapp Oral Infant Drops (Brompheniramine Maleate + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Dimetapp Tab (Brompheniramine Maleate + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Dimetapp-C Syr (Brompheniramine Maleate + Codeine Phosphate + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Hemorrhoidal Ointment (Mineral Oil + Petrolatum + Phenylephrine Hydrochloride + Shark Liver Oil)
Hot Lemon Relief DM Adult (Dextromethorphan Hydrobromide + Pheniramine Maleate + Phenylephrine Hydrochloride)
Hot Lemon Relief Pws (Acetaminophen + Pheniramine Maleate + Phenylephrine Hydrochloride + Vitamin C)
Hot Lemon Relief for Cold Symptoms Ext Str (Acetaminophen + Pheniramine Maleate + Phenylephrine Hydrochloride + Vitamin C)
Hot Lemon Relief for Cold Symptoms Pws (Acetaminophen + Pheniramine Maleate + Phenylephrine Hydrochloride + Vitamin C)
Hot Lemon for Colds Powder (Acetaminophen + Pheniramine Maleate + Phenylephrine Hydrochloride + Vitamin C)
Lemon Relief for Adults (Acetaminophen + Pheniramine Maleate + Phenylephrine Hydrochloride)
Lemon Time (Acetaminophen + Phenylephrine Hydrochloride + Pyrilamine Maleate + Vitamin C)
Neo Citran Extra Strength (Acetaminophen + Pheniramine Maleate + Phenylephrine Hydrochloride)
Neo Citran Nutrasweet (Acetaminophen + Pheniramine Maleate + Phenylephrine Hydrochloride)
Neo Citran Powder (Acetaminophen + Pheniramine Maleate + Phenylephrine Hydrochloride + Vitamin C)
Neo Citran a Powder (Pheniramine Maleate + Phenylephrine Hydrochloride + Vitamin C)
Neo Synephrine Nasal Spray (Phenylephrine Hydrochloride + Thenyldiamine Hcl.)
Neo-Synephrine Nasal Spray (Phenylephrine Hydrochloride + Thenyldiamine Hcl.)
Nezger Tab (Acetylsalicylic Acid + Diphenylpyraline Hydrochloride + Guaifenesin + Phenylephrine Hydrochloride)
Novahistex C (Codeine Phosphate + Phenylephrine Hydrochloride)
Novahistex Dh Expectorant (Guaifenesin + Hydrocodone Bitartrate + Phenylephrine Hydrochloride)
Occu-Cal Drops (Boric Acid + Phenylephrine Hydrochloride + Sodium Borate)
Occu-Cal Lotion (Boric Acid + Phenylephrine Hydrochloride + Sodium Borate)
Pharmetapp Elixir (Brompheniramine Maleate + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Phenergan VC Expectorant Syr (Phenylephrine Hydrochloride + Potassium Guaiacol Sulphonate + Promethazine Hydrochloride)
Phenergan VC Expectorant W Codeine Liq (Codeine Phosphate + Phenylephrine Hydrochloride + Potassium Guaiacol Sulphonate + Promethazine Hydrochloride)
Soframycin Nasal Spray (Framycetin Sulfate + Gramicidin + Phenylephrine Hydrochloride)
Tantapp Elixir (Brompheniramine Maleate + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride)
Vasosulf Oph Soln (Phenylephrine Hydrochloride + Sulfacetamide Sodium)

# Brand_Names:
AK-Dilate
AK-Nefrin
Adrianol
Alcon Efrin
Alconefrin Nasal Drops 12
Alconefrin Nasal Drops 25
Alconefrin Nasal Drops 50
Alconefrin Nasal Spray 25
Biomydrin
Dilatair
Dionephrine
Doktors
Duration
I-Phrine
Isophrim
Isophrin
Isopto Frin
M-Sympathol
M-Sympatol
M-Synephrine
Mesaton
Mesatone
Mesatonum
Metasympatol
Metsatonum
Mezaton
Minims Phenylephrine
Mydfrin
Neo-Synephrine
Neo-Synephrine Nasal Drops
Neo-Synephrine Nasal Jelly
Neo-Synephrine Nasal Spray
Neofrin
Neophryn
Neosynephrine
Nostril
Nostril Spray Pump
Nostril Spray Pump Mild
Ocu-Phrin Sterile Eye Drops
Ocugestrin
Phenoptic
Prefrin
Prefrin Liquifilm
Pyracort D
Relief Eye Drops for Red Eyes
Rhinall
Spersaphrine
Vicks Sinex
Visadron

# CAS_Registry_Number:
59-42-7

# ChEBI_ID:
8093

# Chemical_Formula:
C9H13NO2

# Chemical_IUPAC_Name:
3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2238400

# Description:
Phenylephrine is a sympathomimetic amine that acts predominantly on &alpha;-adrenergic receptors. It is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.

# Dosage_Forms:
Cream	Topical
Injection, solution	Intramuscular
Injection, solution	Intravenous
Liquid	Ophthalmic
Ointment	Topical
Strip	Oral
Suppository	Rectal
Tablet	Oral

# Drug_Category:
Adrenergic alpha-Agonists
Cardiotonic Agents
Mydriatics
Nasal Decongestants
Sympathomimetics
Vasoconstrictor Agents

# Drug_Interactions:
Alseroxylon	Increased arterial pressure
Amitriptyline	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of phenylephrine.
Amoxapine	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of phenylephrine.
Clomipramine	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of phenylephrine.
Deserpidine	Increased arterial pressure
Desipramine	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of phenylephrine.
Doxepin	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of phenylephrine.
Ergonovine	Possible marked increase of arterial pressure
Guanethidine	Phenylephrine may decrease the effect of guanethidine.
Imipramine	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of phenylephrine.
Iobenguane	Sympathomimetic that increase chances of producing a false negative imaging result
Isocarboxazid	Increased arterial pressure
Linezolid	Possible increase of arterial pressure
Methyldopa	Increased arterial pressure
Methylergonovine	Possible marked increase of arterial pressure
Midodrine	Increased arterial pressure
Moclobemide	Moclobemide increases the sympathomimetic effect of phenylephrine.
Nortriptyline	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of phenylephrine.
Oxytocin	Possible marked increase of arterial pressure
Pargyline	Increased arterial pressure
Phenelzine	Increased arterial pressure
Protriptyline	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of phenylephrine.
Rasagiline	Increased arterial pressure
Reserpine	Increased arterial pressure
Tranylcypromine	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Phenylephrine. Concomitant therapy should be avoided.
Trimipramine	Trimipramine may increase the vasopressor effect of the alpha1-agonist, Phenylephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.31

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Freely soluble in water

# Food_Interactions:
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Phenylephrine

# HET_ID:
Not Available

# Half_Life:
2.1 to 3.4 hours

# InChI_Identifier:
InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1

# InChI_Key:
InChIKey=SONNWYBIRXJNDC-VIFPVBQESA-N

# Indication:
Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.

# KEGG_Compound_ID:
C07441

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
388

# Mechanism_Of_Action:
In general, &alpha;<sub>1</sub>-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. &alpha;<sub>1</sub>-receptors are 7-transmembrane domain receptors coupled to G proteins, G<sub>q/11</sub>. Three &alpha;<sub>1</sub>-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: &alpha;<sub>1A</sub> (chromosome 8), &alpha;<sub>1B</sub> (chromosome 5), and &alpha;<sub>1D</sub> (chromosome 20). Phenylephrine appears to act similarly on all three receptor subtypes. All three receptor subtypes appear to be involved in maintaining vascular tone. The &alpha;<sub>1A</sub>-receptor maintains basal vascular tone while the &alpha;<sub>1B</sub>-receptor mediates the vasocontrictory effects of exogenous &alpha;<sub>1</sub>-agonists. Activation of the &alpha;<sub>1</sub>-receptor activates G<sub>q</sub>-proteins, which results in intracellular stimulation of phospholipases C, A<sub>2</sub>, and D. This results in mobilization of Ca<sup>2+</sup> from intracellular stores, activation of mitogen-activated kinase and PI<sub>3</sub> kinase pathways and subsequent vasoconstriction. Phenylephrine produces its local and systemic actions by acting on &alpha;<sub>1</sub>-adrenergic receptors peripheral vascular smooth muscle. Stimulation of the &alpha;<sub>1</sub>-adrenergic receptors results in contraction arteriolar smooth muscle in the periphery. Phenylephrine decreases nasal congestion by acting on &alpha;<sub>1</sub>-adrenergic receptors in the arterioles of the nasal mucosa to produce constriction; this leads to decreased edema and increased drainage of the sinus cavities.

# Melting_Point:
140-145 °C

# Molecular_Weight_Avg:
167.205

# Molecular_Weight_Mono:
167.094628665

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drugs/otc/otc-mono.aspx?contentFileName=DNX0283.xml&contentName=PHENYLEPHRINE+HYDROCHLORIDE&contentId=4034

# Pathways:
Not Available

# PharmGKB_ID:
PA450935

# Pharmacology:
Phenylephrine is a powerful vasoconstrictor. It is used as a nasal decongestant and cardiotonic agent. Phenylephrine is a postsynaptic &alpha;<sub>1</sub>-receptor agonist with little effect on &beta;-receptors of the heart. Parenteral administration of phenylephrine causes a rise in systolic and diastolic pressures, a slight decrease in cardiac output, and a considerable increase in peripheral resistance; most vascular beds are constricted, and renal, splanchnic, cutaneous, and limb blood flows are reduced while coronary blood flow is increased. Phenelephrine also causes pulmonary vessel constriction and subsequent increase in pulmonary arterial pressure. Vasoconstriction in the mucosa of the respiratory tract leads to decreased edema and increased drainage of sinus cavities.

# Predicted_LogP_Hydrophobicity:
-0.69

# Predicted_LogS:
-0.88

# Predicted_Water_Solubility:
2.20e+01 g/l

# Primary_Accession_No:
DB00388

# Protein_Binding:
95% binding-plasma proteins

# PubChem_Compound_ID:
6041

# PubChem_Substance_ID:
46506961

# RxList_Link:
http://www.rxlist.com/cgi/generic3/phenyleph.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00365

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CNC[C@H](O)C1=CC(O)=CC=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Fenilefrina [INN-Spanish]
L-Phenylephedrine
L-Phenylephrine
M-Methylaminoethanolphenol
M-Oxedrine
Metaoxedrin
Metaoxedrine
Metaoxedrinum
Metasynephrine
Phenylephrinum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:18 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Phenylephrine

# pKa_Isoelectric_Point:
8.97

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
MAOA

# Phase_1_Metabolizing_Enzyme_1_ID:
3941

# Phase_1_Metabolizing_Enzyme_1_Name:
Amine oxidase [flavin-containing] A

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Amine oxidase [flavin-containing] A
MENQEKASIAGHMFDVVVIGGGISGLSAAKLLTEYGVSVLVLEARDRVGGRTYTIRNEHV
DYVDVGGAYVGPTQNRILRLSKELGIETYKVNVSERLVQYVKGKTYPFRGAFPPVWNPIA
YLDYNNLWRTIDNMGKEIPTDAPWEAQHADKWDKMTMKELIDKICWTKTARRFAYLFVNI
NVTSEPHEVSALWFLWYVKQCGGTTRIFSVTNGGQERKFVGGSGQVSERIMDLLGDQVKL
NHPVTHVDQSSDNIIIETLNHEHYECKYVINAIPPTLTAKIHFRPELPAERNQLIQRLPM
GAVIKCMMYYKEAFWKKKDYCGCMIIEDEDAPISITLDDTKPDGSLPAIMGFILARKADR
LAKLHKEIRKKKICELYAKVLGSQEALHPVHYEEKNWCEEQYSGGCYTAYFPPGIMTQYG
RVIRQPVGRIFFAGTETATKWSGYMEGAVEAGERAAREVLNGLGKVTEKDIWVQEPESKD
VPAVEITHTFWERNLPSVSGLLKIIGFSTSVTALGFVLYKYKLLPRS

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P21397

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP1A2

# Phase_1_Metabolizing_Enzyme_2_ID:
4200

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 1A2

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P05177

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17584443	Martinez-Salas SG, Campos-Peralta JM, Pares-Hipolito J, Gallardo-Ortiz IA, Ibarra M, Villalobos-Molina R: Alpha1A-adrenoceptors predominate in the control of blood pressure in mouse mesenteric vascular bed. Auton Autacoid Pharmacol. 2007 Jul;27(3):137-42.
17658513	Tomiyama Y, Kobayashi K, Tadachi M, Kobayashi S, Inada Y, Kobayashi M, Yamazaki Y: Expressions and mechanical functions of alpha(1)-adrenoceptor subtypes in hamster ureter. Eur J Pharmacol. 2007 Nov 14;573(1-3):201-5. Epub 2007 Jul 6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
ADRA1A

# Drug_Target_1_GenBank_ID_Gene:
D25235

# Drug_Target_1_GenBank_ID_Protein:
433201

# Drug_Target_1_GeneCard_ID:
ADRA1A

# Drug_Target_1_Gene_Name:
ADRA1A

# Drug_Target_1_Gene_Sequence:
>1401 bp
ATGGTGTTTCTCTCGGGAAATGCTTCCGACAGCTCCAACTGCACCCAACCGCCGGCACCG
GTGAACATTTCCAAGGCCATTCTGCTCGGGGTGATCTTGGGGGGCCTCATTCTTTTCGGG
GTGCTGGGTAACATCCTAGTGATCCTCTCCGTAGCCTGTCACCGACACCTGCACTCAGTC
ACGCACTACTACATCGTCAACCTGGCGGTGGCCGACCTCCTGCTCACCTCCACGGTGCTG
CCCTTCTCCGCCATCTTCGAGGTCCTAGGCTACTGGGCCTTCGGCAGGGTCTTCTGCAAC
ATCTGGGCGGCAGTGGATGTGCTGTGCTGCACCGCGTCCATCATGGGCCTCTGCATCATC
TCCATCGACCGCTACATCGGCGTGAGCTACCCGCTGCGCTACCCAACCATCGTCACCCAG
AGGAGGGGTCTCATGGCTCTGCTCTGCGTCTGGGCACTCTCCCTGGTCATATCCATTGGA
CCCCTGTTCGGCTGGAGGCAGCCGGCCCCCGAGGACGAGACCATCTGCCAGATCAACGAG
GAGCCGGGCTACGTGCTCTTCTCAGCGCTGGGCTCCTTCTACCTGCCTCTGGCCATCATC
CTGGTCATGTACTGCCGCGTCTACGTGGTGGCCAAGAGGGAGAGCCGGGGCCTCAAGTCT
GGCCTCAAGACCGACAAGTCGGACTCGGAGCAAGTGACGCTCCGCATCCATCGGAAAAAC
GCCCCGGCAGGAGGCAGCGGGATGGCCAGCGCCAAGACCAAGACGCACTTCTCAGTGAGG
CTCCTCAAGTTCTCCCGGGAGAAGAAAGCGGCCAAAACGCTGGGCATCGTGGTCGGCTGC
TTCGTCCTCTGCTGGCTGCCTTTTTTCTTAGTCATGCCCATTGGGTCTTTCTTCCCTGAT
TTCAAGCCCTCTGAAACAGTTTTTAAAATAGTATTTTGGCTCGGATATCTAAACAGCTGC
ATCAACCCCATCATATACCCATGCTCCAGCCAAGAGTTCAAAAAGGCCTTTCAGAATGTC
TTGAGAATCCAGTGTCTCCGCAGAAAGCAGTCTTCCAAACATGCCCTGGGCTACACCCTG
CACCCGCCCAGCCAGGCCGTGGAAGGGCAACACAAGGACATGGTGCGCATCCCCGTGGGA
TCAAGAGAGACCTTCTACAGGATCTCCAAGACGGATGGCGTTTGTGAATGGAAATTTTTC
TCTTCCATGCCCCGTGGATCTGCCAGGATTACAGTGTCCAAAGACCAATCCTCCTGTACC
ACAGCCCGGGTGAGAAGTAAAAGCTTTTTGGAGGTCTGCTGCTGTGTAGGGCCCTCAACC
CCCAGCCTTGACAAGAACCATCAAGTTCCAACCATTAAGGTCCACACCATCTCCCTCAGT
GAGAACGGGGAGGAAGTCTAG

# Drug_Target_1_General_Function:
Involved in alpha1-adrenergic receptor activity

# Drug_Target_1_General_References:
7737411	Hirasawa A, Shibata K, Horie K, Takei Y, Obika K, Tanaka T, Muramoto N, Takagaki K, Yano J, Tsujimoto G: Cloning, functional expression and tissue distribution of human alpha 1c-adrenoceptor splice variants. FEBS Lett. 1995 Apr 24;363(3):256-60.
7815325	Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, et al.: Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42.
8024574	Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski D, Strader CD, Bayne M: Cloning, expression and characterization of human alpha adrenergic receptors alpha 1a, alpha 1b and alpha 1c. Biochem Biophys Res Commun. 1994 Jun 30;201(3):1296-304.
8183249	Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.
8396931	Hirasawa A, Horie K, Tanaka T, Takagaki K, Murai M, Yano J, Tsujimoto G: Cloning, functional expression and tissue distribution of human cDNA for the alpha 1C-adrenergic receptor. Biochem Biophys Res Commun. 1993 Sep 15;195(2):902-9.
8564208	Tseng-Crank J, Kost T, Goetz A, Hazum S, Roberson KM, Haizlip J, Godinot N, Robertson CN, Saussy D: The alpha 1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. Br J Pharmacol. 1995 Aug;115(8):1475-85.
9490024	Chang DJ, Chang TK, Yamanishi SS, Salazar FH, Kosaka AH, Khare R, Bhakta S, Jasper JR, Shieh IS, Lesnick JD, Ford AP, Daniels DV, Eglen RM, Clarke DE, Bach C, Chan HW: Molecular cloning, genomic characterization and expression of novel human alpha1A-adrenoceptor isoforms. FEBS Lett. 1998 Jan 30;422(2):279-83.

# Drug_Target_1_HGNC_ID:
HGNC:277

# Drug_Target_1_HPRD_ID:
00081

# Drug_Target_1_ID:
556

# Drug_Target_1_Locus:
8p21-p11.2

# Drug_Target_1_Molecular_Weight:
51487

# Drug_Target_1_Name:
Alpha-1A adrenergic receptor

# Drug_Target_1_Number_of_Residues:
466

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Amlodipine Pathway	SMP00376
Benazepril Pathway	SMP00145
Captopril Pathway	SMP00146
Carvedilol Pathway	SMP00367
Cilazapril Pathway	SMP00147
Diltiazem Pathway	SMP00359
Enalapril Pathway	SMP00148
Felodipine Pathway	SMP00377
Fosinopril Pathway	SMP00149
Isradipine Pathway	SMP00378
Labetalol Pathway	SMP00368
Lisinopril Pathway	SMP00150
Moexipril Pathway	SMP00151
Nifedipine Pathway	SMP00379
Nimodipine Pathway	SMP00380
Nisoldipine Pathway	SMP00381
Nitrendipine Pathway	SMP00382
Perindopril Pathway	SMP00152
Quinapril Pathway	SMP00153
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Trandolapril Pathway	SMP00157
Verapamil Pathway	SMP00375

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Alpha-1A adrenergic receptor
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSV
THYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCII
SIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINE
EPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKN
APAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPD
FKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTL
HPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCT
TARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSENGEEV

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins

# Drug_Target_1_SwissProt_ID:
P35348

# Drug_Target_1_SwissProt_Name:
ADA1A_HUMAN

# Drug_Target_1_Synonyms:
Alpha 1A- adrenoreceptor
Alpha 1A-adrenoceptor
Alpha adrenergic receptor 1c
Alpha-1C adrenergic receptor

# Drug_Target_1_Theoretical_pI:
9.23

# Drug_Target_1_Transmembrane_Regions:
28-51
65-88
100-122
144-167
182-205
274-297
306-329

# Drug_Target_2_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
ADRA1B

# Drug_Target_2_GenBank_ID_Gene:
M99589

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
ADRA1B

# Drug_Target_2_Gene_Name:
ADRA1B

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Involved in alpha1-adrenergic receptor activity

# Drug_Target_2_General_References:
1328250	Ramarao CS, Denker JM, Perez DM, Gaivin RJ, Riek RP, Graham RM: Genomic organization and expression of the human alpha 1B-adrenergic receptor. J Biol Chem. 1992 Oct 25;267(30):21936-45.
7815325	Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, et al.: Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42.
8183249	Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.

# Drug_Target_2_HGNC_ID:
HGNC:278

# Drug_Target_2_HPRD_ID:
00080

# Drug_Target_2_ID:
632

# Drug_Target_2_Locus:
5q23-q32

# Drug_Target_2_Molecular_Weight:
56837

# Drug_Target_2_Name:
Alpha-1B adrenergic receptor

# Drug_Target_2_Number_of_Residues:
520

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_2_Protein_Sequence:
>Alpha-1B adrenergic receptor
MNPDLDTGHNTSAPAHWGELKNANFTGPNQTSSNSTLPQLDITRAISVGLVLGAFILFAI
VGNILVILSVACNRHLRTPTNYFIVNLAMADLLLSFTVLPFSAALEVLGYWVLGRIFCDI
WAAVDVLCCTASILSLCAISIDRYIGVRYSLQYPTLVTRRKAILALLSVWVLSTVISIGP
LLGWKEPAPNDDKECGVTEEPFYALFSSLGSFYIPLAVILVMYCRVYIVAKRTTKNLEAG
VMKEMSNSKELTLRIHSKNFHEDTLSSTKAKGHNPRSSIAVKLFKFSREKKAAKTLGIVV
GMFILCWLPFFIALPLGSLFSTLKPPDAVFKVVFWLGYFNSCLNPIIYPCSSKEFKRAFV
RILGCQCRGRGRRRRRRRRRLGGCAYTYRPWTRGGSLERSQSRKDSLDDSGSCLSGSQRT
LPSASPSPGYLGRGAPPPVELCAFPEWKAPGALLSLPAPEPPGRRGRHDSGPLFTFKLLT
EPESPGTDGGASNGGCEAAADVANGQPGFKSNMPLAPGQF

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system

# Drug_Target_2_SwissProt_ID:
P35368

# Drug_Target_2_SwissProt_Name:
ADA1B_HUMAN

# Drug_Target_2_Synonyms:
Alpha 1B- adrenoreceptor
Alpha 1B-adrenoceptor

# Drug_Target_2_Theoretical_pI:
9.79

# Drug_Target_2_Transmembrane_Regions:
46-70
84-105
116-141
162-182
202-224
296-319
327-340

# Drug_Target_3_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
Not Available

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
ADRA1D

# Drug_Target_3_GenBank_ID_Gene:
M76446

# Drug_Target_3_GenBank_ID_Protein:
177807

# Drug_Target_3_GeneCard_ID:
ADRA1D

# Drug_Target_3_Gene_Name:
ADRA1D

# Drug_Target_3_Gene_Sequence:
>1719 bp
ATGACTTTCCGCGATCTCCTGAGCGTCAGTTTCGAGGGACCCCGCCCGGACAGCAGCGCA
GGGGGCTCCAGCGCGGGCGGCGGCGGGGGCAGCGCGGGCGGCGCGGCCCCCTCGGAGGGC
CCGGCGGTGGGCGGCGTGCCGGGGGGCGCGGGCGGCGGCGGCGGCGTGGTGGGCGCAGGC
AGCGGCGAGGACAACCGGAGCTCCGCGGGGGAGCCGGGGAGCGCGGGCGCGGGCGGCGAC
GTGAATGGCACGGCGGCCGTCGGGGGACTGGTGGTGAGCGCGCAGGGCGTGGGCGTGGGC
GTCTTCCTGGCAGCCTTCATCCTTATGGCCGTGGCAGGTAACCTGCTTGTCATCCTCTCA
GTGGCCTGCAACCGCCACCTGCAGACCGTCACCAACTATTTCATCGTGAACCTGGCCGTG
GCCGACCTGCTGCTGAGCGCCACCGTACTGCCCTTCTCGGCCACCATGGAGGTTCTGGGC
TTCTGGGCCTTTGGCCGCGCCTTCTGCGACGTATGGGCCGCCGTGGACGTGCTGTGCTGC
ACGGCCTCCATCCTCAGCCTCTGCACCATCTCCGTGGACCGGTACGTGGGCGTGCGCCAC
TCACTCAAGTACCCAGCCATCATGACCGAGCGCAAGGCGGCCGCCATCCTGGCCCTGCTC
TGGGTCGTAGCCCTGGTGGTGTCCGTAGGGCCCCTGCTGGGCTGGAAGGAGCCCGTGCCC
CCTGACGAGCGCTTCTGCGGTATCACCGAGGAGGCGGGCTACGCTGTCTTCTCCTCCGTG
TGCTCCTTCTACCTGCCCATGGCGGTCATCGTGGTCATGTACTGCCGCGTGTACGTGGTC
GCGCGCAGCACCACGCGCAGCCTCGAGGCAGGCGTCAAGCGCGAGCGAGGCAAGGCCTCC
GAGGTGGTGCTGCGCATCCACTGTCGCGGCGCGGCCACGGGCGCCGACGGGGCGCACGGC
ATGCGCAGCGCCAAGGGCCACACCTTCCGCAGCTCGCTCTCCGTGCGCCTGCTCAAGTTC
TCCCGTGAGAAGAAAGCGGCCAAGACTCTGGCCATCGTCGTGGGTGTCTTCGTGCTCTGC
TGGTTCCCTTTCTTCTTTGTCCTGCCGCTCGGCTCCTTGTTCCCGCAGCTGAAGCCATCG
GAGGGCGTCTTCAAGGTCATCTTCTGGCTCGGCTACTTCAACAGCTGCGTGAACCCGCTC
ATCTACCCCTGTTCCAGCCGCGAGTTCAAGCGCGCCTTCCTCCGTCTCCTGCGCTGCCAG
TGCCGTCGTCGCCGGCGCCGCCGCCCTCTCTGGCGTGTCTACGGCCACCACTGGCGGGCC
TCCACCAGCGGCCTGCGCCAGGACTGCGCCCCGAGTTCGGGCGACGCGCCCCCCGGAGCG
CCGCTGGCCCTCACCGCGCTCCCCGACCCCGACCCCGAACCCCCAGGCACGCCCGAGATG
CAGGCTCCGGTCGCCAGCCGTCGAAAGCCACCCAGCGCCTTCCGCGAGTGGAGGCTGCTG
GGGCCGTTCCGGAGACCCACGACCCAGCTGCGCGCCAAAGTCTCCAGCCTGTCGCACAAG
ATCCGCGCCGGGGGCGCGCAGCGCGCAGAGGCAGCGTGCGCCCAGCGCTCAGAGGTGGAG
GCTGTGTCCCTAGGCGTCCCACACGAGGTGGCCGAGGGCGCCACCTGCCAGGCCTACGAA
TTGGCCGACTACAGCAACCTACGGGAGACCGATATTTAA

# Drug_Target_3_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_3_General_References:
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
1656955	Bruno JF, Whittaker J, Song JF, Berelowitz M: Molecular cloning and sequencing of a cDNA encoding a human alpha 1A adrenergic receptor. Biochem Biophys Res Commun. 1991 Sep 30;179(3):1485-90.
7746284	Esbenshade TA, Hirasawa A, Tsujimoto G, Tanaka T, Yano J, Minneman KP, Murphy TJ: Cloning of the human alpha 1d-adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells. Mol Pharmacol. 1995 May;47(5):977-85.
7815325	Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, et al.: Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42.
8024574	Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski D, Strader CD, Bayne M: Cloning, expression and characterization of human alpha adrenergic receptors alpha 1a, alpha 1b and alpha 1c. Biochem Biophys Res Commun. 1994 Jun 30;201(3):1296-304.
8183249	Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.

# Drug_Target_3_HGNC_ID:
HGNC:280

# Drug_Target_3_HPRD_ID:
00079

# Drug_Target_3_ID:
789

# Drug_Target_3_Locus:
20p13

# Drug_Target_3_Molecular_Weight:
60463

# Drug_Target_3_Name:
Alpha-1D adrenergic receptor

# Drug_Target_3_Number_of_Residues:
572

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_3_Protein_Sequence:
>Alpha-1D adrenergic receptor
MTFRDLLSVSFEGPRPDSSAGGSSAGGGGGSAGGAAPSEGPAVGGVPGGAGGGGGVVGAG
SGEDNRSSAGEPGSAGAGGDVNGTAAVGGLVVSAQGVGVGVFLAAFILMAVAGNLLVILS
VACNRHLQTVTNYFIVNLAVADLLLSATVLPFSATMEVLGFWAFGRAFCDVWAAVDVLCC
TASILSLCTISVDRYVGVRHSLKYPAIMTERKAAAILALLWVVALVVSVGPLLGWKEPVP
PDERFCGITEEAGYAVFSSVCSFYLPMAVIVVMYCRVYVVARSTTRSLEAGVKRERGKAS
EVVLRIHCRGAATGADGAHGMRSAKGHTFRSSLSVRLLKFSREKKAAKTLAIVVGVFVLC
WFPFFFVLPLGSLFPQLKPSEGVFKVIFWLGYFNSCVNPLIYPCSSREFKRAFLRLLRCQ
CRRRRRRRPLWRVYGHHWRASTSGLRQDCAPSSGDAPPGAPLALTALPDPDPEPPGTPEM
QAPVASRRKPPSAFREWRLLGPFRRPTTQLRAKVSSLSHKIRAGGAQRAEAACAQRSEVE
AVSLGVPHEVAEGATCQAYELADYSNLRETDI

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium

# Drug_Target_3_SwissProt_ID:
P25100

# Drug_Target_3_SwissProt_Name:
ADA1D_HUMAN

# Drug_Target_3_Synonyms:
Alpha 1D- adrenoreceptor
Alpha 1D-adrenoceptor
Alpha adrenergic receptor 1a
Alpha-1A adrenergic receptor

# Drug_Target_3_Theoretical_pI:
9.44

# Drug_Target_3_Transmembrane_Regions:
96-121
134-159
170-192
214-238
252-275
349-373
381-405

#END_DRUGCARD DB00388
